**Author details**

Derek B. Oien1 , Jeremy Chien<sup>2</sup> , Julian Molina1 and Viji Shridhar1 \*

1 Mayo Clinic, Rochester, Minnesota, USA

2 University of California Davis Health, Sacramento, California, USA

\*Address all correspondence to: shridhar.vijayalakshmi@mayo.edu

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**53**

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

[1] Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. International Journal of Occupational and Environmental

Seminars in Respiratory and Critical Care Medicine. 2011;**32**:102-110

mesothelioma: Final report of a phase II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;**26**:3567-3572

[9] Simon GR, Verschraegen CF, Janne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy

for patients with peritoneal

[10] Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Investigation.

[11] Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD,

[12] Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal

[13] Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.

Surgery. 2013;**153**:779-786

[14] Pretorius RG, Petrilli ES, Kean CK, Ford LC, Hoeschele JD, Lagasse LD. Comparison of the iv and

chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

2003;**21**:682-689

2000;**18**:3912-3917

2009;**27**:6237-6242

[2] Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: A review. Annals of Translational

[3] Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: Review of 123 patients.

[4] Finn RS, Brims FJH, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem findings of malignant pleural mesothelioma: A twocenter study of 318 patients. Chest.

[5] Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA: A Cancer Journal for Clinicians. 2019;**69**:402-429

[6] Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma. Translational Lung Cancer Research. 2018;**7**:599-608

[7] Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

[8] Campbell NP, Kindler HL. Update on malignant pleural mesothelioma.

2003;**21**:2636-2644

**References**

Health. 2013;**19**:1-10

Medicine. 2017;**5**:236

2012;**142**:1267-1273

Cancer. 1982;**49**:2431-2435

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

## **References**

*Mesothelioma*

this manuscript.

**Conflict of interest**

American Cancer Society—Kirby Foundation Postdoctoral Fellowship (Oien, PF-17-241-01-CCG). These sponsors had no involvement in any of the design or writing of this article. The authors thank Caleb Swalve for assistance in preparing

The authors have no conflicts of interest to declare.

**52**

**Author details**

Derek B. Oien1

, Jeremy Chien<sup>2</sup>

1 Mayo Clinic, Rochester, Minnesota, USA

provided the original work is properly cited.

, Julian Molina1

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

2 University of California Davis Health, Sacramento, California, USA

\*Address all correspondence to: shridhar.vijayalakshmi@mayo.edu

and Viji Shridhar1

\*

[1] Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. International Journal of Occupational and Environmental Health. 2013;**19**:1-10

[2] Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: A review. Annals of Translational Medicine. 2017;**5**:236

[3] Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: Review of 123 patients. Cancer. 1982;**49**:2431-2435

[4] Finn RS, Brims FJH, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem findings of malignant pleural mesothelioma: A twocenter study of 318 patients. Chest. 2012;**142**:1267-1273

[5] Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA: A Cancer Journal for Clinicians. 2019;**69**:402-429

[6] Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma. Translational Lung Cancer Research. 2018;**7**:599-608

[7] Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;**21**:2636-2644

[8] Campbell NP, Kindler HL. Update on malignant pleural mesothelioma.

Seminars in Respiratory and Critical Care Medicine. 2011;**32**:102-110

[9] Simon GR, Verschraegen CF, Janne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: Final report of a phase II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;**26**:3567-3572

[10] Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Investigation. 2003;**21**:682-689

[11] Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2000;**18**:3912-3917

[12] Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;**27**:6237-6242

[13] Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;**153**:779-786

[14] Pretorius RG, Petrilli ES, Kean CK, Ford LC, Hoeschele JD, Lagasse LD. Comparison of the iv and ip routes of administration of cisplatin in dogs. Cancer Treatment Reports. 1981;**65**:1055-1062

[15] Neuwirth MG, Alexander HR, Karakousis GC. Then and now: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. Journal of Gastrointestinal Oncology. 2016;**7**:18-28

[16] Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports. 1978;**62**:1-11

[17] Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics. 2016;**48**:407-416

[18] Hmeljak J, Sanchez-Vega F, Hoadley KA. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery. 2018;**8**:1548-1565

[19] Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. The mRNA expression of SETD2 in human breast cancer: Correlation with clinicopathological parameters. BMC Cancer. 2009;**9**:290

[20] Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics. 2011;**43**:1022-1025

[21] Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Research. 2015;**75**:264-269

[22] Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2015;**10**:565-576

[23] Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proceedings of the National Academy of Sciences of the United States of America. 2016;**113**:13432-13437

[24] Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017;**546**:549-553

[25] Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death & Differentiation. 2017;**24**:1694-1704

[26] LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent. Transformation. 2015;**21**:1344-1349

[27] Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. Journal of the National Cancer Institute. 2018;**110**:1328-1341

[28] Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;**35**:537-548

[29] Zhang WQ, Dai YY. Targeting YAP in malignant pleural mesothelioma.

**55**

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

Journal of Cellular and Molecular Medicine. 2017;**21**:2663-2676

pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial. Clinical Cancer Research. 2019;**25**:5759-5765

[36] Tsao AS, Miao J, Wistuba II,

Vogelzang NJ, Heymach JV, Fossella FV, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;**37**:2537-2547

[37] Buikhuisen WA, Scharpfenecker M,

Tinteren H, Baas P, et al. Study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: A single-center trial combining clinical and translational outcomes. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2016;**11**:758-768

[38] Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with

pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A doubleblind, randomised, placebo-controlled phase 3 trial. The Lancer Respiratory

Medicine. 2019;**7**:569-580

2018;**13**:S338-S339

[39] Nowak A, Kok P, Lesterhuis W, Hughes B, Brown C, Kao S, et al. OA08.02 DREAM-A phase 2 trial of durvalumab with first line

chemotherapy in mesothelioma: Final result. Journal of Thoracic Oncology.

[40] Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent

malignant pleural mesothelioma (INITIATE): Results of a prospective,

Griffioen AW, Korse CM, van

[30] Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017;**23**:3191-3202

[31] Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2)

gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Research. 1995;**55**:1227-1231

mesotheliomas. Proceedings of the National Academy of Sciences of the United States of America.

[33] Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-

Cancer. 2019;**14**:276-287

Rivera E, Elsbernd L, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung

[34] Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin Cisplatin Pemetrexed study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2016;**387**:1405-1414

[35] Eberst G, Anota A, Scherpereel A, Mazieres J. Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant

1995;**92**:10854-10858

[32] Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

Journal of Cellular and Molecular Medicine. 2017;**21**:2663-2676

*Mesothelioma*

1981;**65**:1055-1062

Oncology. 2016;**7**:18-28

ip routes of administration of cisplatin in dogs. Cancer Treatment Reports.

[22] Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung

[23] Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proceedings of the National Academy of Sciences of the United States of America.

[24] Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature.

[25] Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death & Differentiation. 2017;**24**:1694-1704

[26] LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al.

Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. Journal of the National Cancer Institute. 2018;**110**:1328-1341

[28] Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;**35**:537-548

[29] Zhang WQ, Dai YY. Targeting YAP in malignant pleural mesothelioma.

Loss of BAP1 function leads to EZH2-dependent. Transformation.

[27] Walpole S, Pritchard AL,

2015;**21**:1344-1349

Cancer. 2015;**10**:565-576

2016;**113**:13432-13437

2017;**546**:549-553

[15] Neuwirth MG, Alexander HR, Karakousis GC. Then and now: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. Journal of Gastrointestinal

[16] Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer

Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics.

Treatment Reports. 1978;**62**:1-11

[18] Hmeljak J, Sanchez-Vega F, Hoadley KA. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery.

[19] Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. The mRNA expression of SETD2 in human breast cancer: Correlation with clinicopathological parameters. BMC Cancer.

[20] Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature

Genetics. 2011;**43**:1022-1025

[21] Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Research.

[17] Bueno R, Stawiski EW,

2016;**48**:407-416

2018;**8**:1548-1565

2009;**9**:290

**54**

2015;**75**:264-269

[30] Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017;**23**:3191-3202

[31] Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Research. 1995;**55**:1227-1231

[32] Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proceedings of the National Academy of Sciences of the United States of America. 1995;**92**:10854-10858

[33] Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2019;**14**:276-287

[34] Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin Cisplatin Pemetrexed study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2016;**387**:1405-1414

[35] Eberst G, Anota A, Scherpereel A, Mazieres J. Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant

pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial. Clinical Cancer Research. 2019;**25**:5759-5765

[36] Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;**37**:2537-2547

[37] Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P, et al. Study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: A single-center trial combining clinical and translational outcomes. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2016;**11**:758-768

[38] Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A doubleblind, randomised, placebo-controlled phase 3 trial. The Lancer Respiratory Medicine. 2019;**7**:569-580

[39] Nowak A, Kok P, Lesterhuis W, Hughes B, Brown C, Kao S, et al. OA08.02 DREAM-A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: Final result. Journal of Thoracic Oncology. 2018;**13**:S338-S339

[40] Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective,

single-arm, phase 2 trial. The Lancet Respiratory Medicine. 2019;**7**:260-270

[41] Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet. Oncology. 2019;**20**:239-253

[42] Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, et al. Tremelimumab as second-line or thirdline treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet. Oncology. 2017;**18**:1261-1273

[43] Venkatraman D, Anderson A, Digumarthy S, Lizotte PH, Awad MM. Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 2019;**37**:8549-8549

[44] Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A doubleblind, randomized, Phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;**37**:790-798

[45] Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2015;**10**:387-391

[46] Oien DB, Pathoulas CL, Ray U, Thirusangu P, Kalogera E, Shridhar V. Repurposing quinacrine for treatment-refractory cancer. Seminars in Cancer Biology. 2019

[47] Zauderer MG, Szlosarek P, Moulec SL, Popat S, Taylor P, Planchard D, et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. Journal of Clinical Oncology. 2018;**36**:8515-8515

[48] Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;**19**:108

[49] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2017;**12**:1309-1319

[50] Oien DB, Garay T, Eckstein S, Chien J. Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy. Frontiers in Pharmacology. 2017;**8**:970

[51] Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2005;**11**:2300-2304

**57**

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

Govindarajan V, Carreau JH, Gatalica Z, Sharma P, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World Journal of Surgical Oncology.

[52] Foster JM, Radhakrishna U,

[53] Zhang J, Khanna S, Jiang Q,

Alewine C, Miettinen M, Pastan I, et al. Efficacy of anti-mesothelin Immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a

biomarker of tumor response. Clinical Cancer Research: An Official Journal of the American Association for Cancer

Mesothelin-targeted second generation

mesothelin-expressing tumors in vivo.

Research. 2017;**23**:1564-1574

[54] Ye L, Lou Y, Lu L, Fan X.

CAR-T cells inhibit growth of

Experimental and Therapeutic Medicine. 2019;**17**:739-747

2010;**8**:88

*Emerging Drug Therapies for Mesothelioma DOI: http://dx.doi.org/10.5772/intechopen.91752*

*Mesothelioma*

single-arm, phase 2 trial. The Lancet Respiratory Medicine. 2019;**7**:260-270 [46] Oien DB, Pathoulas CL, Ray U, Thirusangu P, Kalogera E, Shridhar V. Repurposing quinacrine for treatment-refractory cancer. Seminars

[47] Zauderer MG, Szlosarek P, Moulec SL, Popat S, Taylor P,

study of the EZH2 inhibitor

Oncology. 2018;**36**:8515-8515

[48] Borchert S, Wessolly M,

isoform affects response of

2017;**12**:1309-1319

of the International Association for the Study of Lung Cancer.

[50] Oien DB, Garay T, Eckstein S, Chien J. Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy. Frontiers in

[51] Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research.

Pharmacology. 2017;**8**:970

2005;**11**:2300-2304

2019;**19**:108

Planchard D, et al. Phase 2, multicenter

tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. Journal of Clinical

Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer.

[49] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A novel BRCA1-associated protein-1

mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. Journal of Thoracic Oncology: Official Publication

in Cancer Biology. 2019

nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet. Oncology. 2019;**20**:239-253

[42] Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, et al. Tremelimumab as second-line or thirdline treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet. Oncology.

[43] Venkatraman D, Anderson A, Digumarthy S, Lizotte PH, Awad MM. Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). Journal of Clinical Oncology.

[44] Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A doubleblind, randomized, Phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;**37**:790-798

[45] Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung

Cancer. 2015;**10**:387-391

2017;**18**:1261-1273

2019;**37**:8549-8549

[41] Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Nivolumab or

**56**

[52] Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World Journal of Surgical Oncology. 2010;**8**:88

[53] Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, et al. Efficacy of anti-mesothelin Immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017;**23**:1564-1574

[54] Ye L, Lou Y, Lu L, Fan X. Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. Experimental and Therapeutic Medicine. 2019;**17**:739-747

**59**

Section 4

Predictive and Prognostic

Biomarkers

Section 4
